JEFFERIES stuft ASTRAZENECA auf Buy
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca auf "Buy" mit einem Kursziel von 18000…
78,250€
0,32%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
JPMORGAN stuft ASTRAZENECA auf Overweight
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca auf "Overweight" mit einem Kursziel von 16000…
Citi raises AstraZeneca earnings forecast and maintains buy rating ahead of second-half pipeline catalysts
Bank lifts 2026 core earnings per share estimate 2% to $10.30 after first-quarter beat, sees positive risk-reward into late-year readouts…
+++ Geschäftszahlen +++: Versicherer Talanx übertrifft Gewinnerwartungen
Iran-Krieg treibt Gewinn von TotalEnergies an +++ Starke Medikamentennachfrage stützt AstraZeneca und GSK an +++ Wacker Chemie verbessert operatives Ergebnis…
FTSE 100 Live: Sluggish start expected as Lloyds, AstraZeneca and Jet2 report
7.15am: FTSE 100 heading for sluggish start The FTSE 100 may be heading for a sluggish start on Wednesday, as…
FTSE 100 Live: Sluggish start as AstraZeneca, Haleon results disappoint
8.15am: FTSE opens in red The FTSE 100 has opened 40 points lower at 10,292. St Jamess Place, GSK and Haleon…
AstraZeneca sticks to its guns after strong first-quarter revenue growth
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, has reconfirmed its full-year 2026 guidance after reporting first-quarter total...…
Citi sees Daiichi supply review as immaterial for AstraZeneca
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, faces no material risk from its Japanese partner Daiichi Sankyos decision…
Saphnelo self-administration approved in the US
27 April 2026Saphnelo approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosusFirst-in-class Saphnelo Pen now…
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
Astrazeneca (AZN) concluded the recent trading session at $192.3, signifying a -1.29% move from its prior days close.…
AstraZenecas Ultomiris Meets Goal in Rare Kidney Disease Study
AZNs Ultomiris hits key goal in IgAN study, showing early proteinuria reduction as it eyes accelerated approval in major markets.…
AstraZenecas tozorakimab treble puts $5bn sales ceiling in sight, says Citi
A third consecutive phase III success for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) tozorakimab in chronic obstructive pulmonary disease (COPD) has reinforced...…
AstraZenecas Ultomiris hits primary endpoint in rare kidney disease trial
AstraZeneca PLCs (LSE:AZN, NASDAQ:AZN) Ultomiris has met its primary endpoint in a phase III trial targeting immunoglobulin A nephropathy (IgAN),…
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Astrazeneca (AZN) reached $201.21 at the closing of the latest trading day, reflecting a -1.55% change compared to its last…
AstraZeneca faces China headwinds and key drug launches as two banks back 20% upside
UBS and Citi both maintain buy ratings on the Anglo-Swedish drugmaker ahead of its first-quarter results, with a rich pipeline…
Result of AGM
9 April 2026Results of Annual General Meeting held on 9 April 2026AstraZeneca PLC announced the results of the voting at…
AZN vs. MRK: Which Oncology Stock Offers Better Investment Potential?
Though both dominate oncology, a stronger growth outlook and clearer targets may give AstraZeneca an edge over Merck.…
The Zacks Analyst Blog Highlights AstraZeneca, HSBC, Walt Disney, Oak Valley Bancorp and BV Financial
AstraZeneca (AZN) leads Zacks Research highlights with strong drug growth and pipeline momentum, while HSBC and Disney navigate costs and…
AstraZeneca Aktie: "Top Pick" mit neuem Rückenwind!
New York (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von Morgan Stanley:Morgan Stanley habe das Kursziel für die Aktie von AstraZeneca plc (ISIN: GB0009895292,…
Top Research Reports for AstraZeneca, HSBC & Walt Disney
AstraZenecas strong drug portfolio and pipeline fuel growth targets, while HSBC restructures and Disney balances streaming gains against rising costs.…
AstraZenecas liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drug
A positive phase three trial result in a hard-to-treat cancer adds fresh momentum to one of AstraZenecas most important growth…
AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns
…
Astrazeneca (AZN) Rises Higher Than Market: Key Facts
Astrazeneca (AZN) concluded the recent trading session at $203.49, signifying a +1.37% move from its prior days close.…
US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported mixed phase three trial data for efzimfotase alfa, its treatment for hypophosphatasia, a rare…
Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPDs hardest-to-treat patients
Fridays positive trial results for tozorakimab mark a significant inflexion point for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), arriving at a moment…
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
In the latest trading session, Astrazeneca (AZN) closed at $188.42, marking a +2.74% move from the previous day.…
AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.…
Stocks making the biggest moves premarket: AstraZeneca, Unity Software, Coinbase & more
These are the stocks posting the largest moves premarket.…
AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares rose 3% to 14,230p, placing the drugmaker at the top of the FTSE 100 leaderboard…
AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares rose 3% to 14,230p, placing the drugmaker at the top of the FTSE 100 leaderboard…
Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know
The latest trading day saw Astrazeneca (AZN) settling at $183.6, representing a -2.82% change from its previous close.…
AstraZenecas Imfinzi Secures Approval for Gastric Cancer in the EU
AZN wins the EU nod for Imfinzi in early gastric and GEJ cancers, backed by strong survival data and expanding…
Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know
Astrazeneca (AZN) concluded the recent trading session at $189.9, signifying a -1.35% move from its prior days close.…
Mineralys (MLYS) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.DATEThursday, March 12, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Jon CongletonChief Financial Officer…
Teilerfolg für Klage gegen AstraZeneca im Prozess um Impfschaden
Sie erhält eine Covid-Impfung und erleidet einen Hörsturz. Nun hat die Frau den Rechtsstreit mit dem Impfstoffhersteller AstraZeneca vor den…
Klage gegen AstraZeneca: Wann Impfstoffhersteller haften
Vor dem Bundesgerichtshof geht es heute um mögliche Ansprüche nach einer Corona-Impfung. Eine Klägerin verlangt Schadensersatz und Auskunft vom Hersteller…
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…
Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial
Broker upgrades odds on AVANZAR lung cancer trial after arguing repeated delays signal strong results in treatment arm Jefferies has…
The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop
Exxon Mobil, Palantir and AstraZeneca lead Zacks latest analyst reports, highlighting strong production growth, AI momentum and a robust drug…
Top Analyst Reports for Exxon Mobil, Palantir & AstraZeneca
Exxon Mobil leads fresh analyst reports as Permian and Guyana output power growth, while Palantirs AI platforms and AstraZenecas drug…
SOPHiA GENETICS (SOPH) Q4 2025 Earnings Transcript
Image source: The Motley Fool.DATEMarch 3, 2026, 8 a.m. ETCALL PARTICIPANTSChief Executive Officer — Jurgi CamblongChief Financial Officer — George…
Salesforce CEO touts company resilience amid software slump
Looking back, it almost seems like a dream. On Aug. 31, 2020, the U.S. had just surpassed six million COVID-19…
LNTH: 2025 Earnings Flash Report
By John Vandermosten, CFANASDAQ:LNTHLantheus Reports 2025 Financial and Operational Results Lantheus Holdings, Inc. (NASDAQ:LNTH) reported financial results yesterday. Revenue was…
AstraZeneca has sector leading replacement power to cope with 2030 patent cliff
The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and immune engagers, according to UBS,...…
Arcus (RCUS) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.DATEWednesday, Feb. 25, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Terry J. RosenPresident —…
IonQ (IONQ) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.DateFeb. 25, 2026 at 4:30 p.m. ETCall participantsChairman and Chief Executive Officer — Niccolo de MasiChief…
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
AZNs stronger growth outlook and 2030 revenue target may outshine PFEs yield and cheaper valuation.…
Fixed-duration Calquence combo approved in US
20 February 2026Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in…
Inside Biotech: AstraZeneca halts generic diabetes pill launch in patent battle with Pharmacor
In a significant patent skirmish for the Australian biotech and pharmaceutical sector, AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured a Federal…
Inside Biotech: AstraZeneca halts generic diabetes pill launch in patent battle with Pharmacor
In a significant patent skirmish for the Australian biotech and pharmaceutical sector, AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured a Federal…